

# Centralized DLCO services

Advanced assessment of lung gas transfer

## Going beyond standard spirometry for greater insights into lung function

Diffusing capacity of the lungs for carbon monoxide (DLCO) is a pulmonary function test that measures the ability of the lungs to transfer gas from ambient air to red blood cells. DLCO measurement is a valuable test for assessing clinical endpoints in asthma, COPD idiopathic pulmonary fibrosis and cystic fibrosis studies. It is also used in clinical research for inhaled drugs targeting non-respiratory indications that might have an impact on diffusing capacity. Repeated DLCO measurements aid in determining disease progression and therapeutic efficacy that would not be obtainable by standard spirometry or imaging.

Independent studies have shown that when different devices and processes are used by respiratory therapists with varying levels of proficiency, DLCO measurements of the same patients can vary by as much as 50% in different labs, compromising both patient safety and study outcomes.

## Centralized DLCO solutions for clinical trials

We offer centralized DLCO services through integration of the ndd® EasyOne Pro device into the Clario EXPERT® platform. Our extensive training programs drive optimal DLCO and spirometry measurements, while ensuring data integrity and plausibility. Clario's experience in data collection provides better data quality, reduced site burden, improved study oversight and shortened timelines. Our cloud-enabled services deliver near real-time evaluation, notifications, expert overread, data reconciliation and reporting.

Without centralization, expect up to 50% DLCO data variability across sites



## DATA SHEET

### Custom configuration

Customize your DLCO measurement configuration based on your protocol needs, testing, review and interpretation of data.

### Increase site and patient performance

Leverage comprehensive site device training and patient coaching

### Convenient set-up and ease of use


Minimal space requirements, high-resolution touch screen, automatic calibration and user guidance supports ATS/ERS standards.

### Real-time notifications and central overread

Real-time inclusion and exclusion criteria evaluation is delivered via email notifications. Central overread by Clario respiratory experts provides quality control, best-test review and criteria re-evaluation within flexible turnaround times.

### Integrate for enhanced data insights

Integrate ECG and eCOA endpoints through additional Clario solutions, as required, or leverage enhanced intelligence tools such as outlier or site performance analysis. Data is securely transmitted via integration with the Clario EXPERT platform.



**Advanced DLCO collection and analysis for your clinical trial.**  
For more information, go to [clario.com](https://clario.com) or email [info@clario.com](mailto:info@clario.com)

Clario generates the richest clinical evidence. Fusing our deep scientific expertise and global scale into the broadest endpoint technology platform, we empower our partners to transform lives.

**Quality and Safety** eResearchTechnology GmbH operates a Quality Management System according to EN ISO 13485 and 21 CFR Part 820.

eResearchTechnology GmbH  
Sieboldstrasse 3  
97230 Estenfeld, Germany

[f /clarioclinical](https://www.facebook.com/clarioclinical) [in @clario-inc](https://www.linkedin.com/company/clario-inc) [@clario](https://twitter.com/clario)

**CLARIO.**

REV2 09JAN2023 | © 2023 eResearchTechnology GmbH. All rights reserved. ndd® and EasyOne Pro® LAB are trademarks of ndd Medical Technologies, Inc. Images of device and technical specifications are subject to change. The availability of the device depends on national regulations and registrations. If the device is available in your country, please contact your local sales representative.